Abstract: Objective To provide the evidence for rational intervention of LDL-C by analyzing its control in coronary heart disease(CHD) patients after coronary stenting. Methods Baseline data before coronary stenting and 1-year follow-up data(including serum LDL-C level, drugs used, diet, exercises) about patients who underwent coronary stenting in 3 hospitals from January 2011 to June 2012 were analyzed. Results A total of 1 274 patients were followed up. The abnormal LDL-C rate was 30.0%, 36.3%, 44.8% respectively when its target value was set at 2.08 mmol/L and 45.7%, 53.4%, 58.6% respectively when its target value was set at 1.82 mmol/L1, 6 and 12 months after coronary stenting(P<0.05). The incidence of major adverse cardiovascular events(MACEs) was significantly higher in patients with their LDL-C ≥ 2.08 mmol/L 6 months after coronary stenting than in those 7-12 months after coronary stenting(7.5% vs 3.7%, P=0.000 8). Multivariate logistic regression analysis revealed that non-adjusted lipid-decreasing statin therapy(OR=2.73, 95%CI:1.89-3.57), baseline LDL-C level ≥ 3.37 mmol/L(OR=2.28, 95%CI:1.76-2.92), poor diet control(OR=1.65, 95%CI:1.21-2.37) and poor medication compliance(OR=1.44, 95%CI:1.09-2.15) were the risk factors for abnormal LDL-C. Conclusion LDL-C is abnormal in a considerable number of patients 1 year after coronary stenting. The incidence of MACEs is high in patients with abnormal LDL-C.